Nyrada Inc
Company Profile
Business description
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. It operates in one segment: research and development of drugs focusing on small molecules with potential therapeutic benefit in areas of medical needs. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.
Contact
180 George Street, Sydney Place
Level 22/23, Salesforce Tower
SydneyNSW2000
AUST: +61 294983390
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Corning’s AI fiber boom is real, but its stock price may be getting out of hand
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
stocks
ASX energy share remains cheap despite strong outlook
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,943.90 | 5.50 | -0.06% |
| CAC 40 | 8,141.92 | 15.90 | -0.19% |
| DAX 40 | 24,083.53 | 45.45 | -0.19% |
| Dow JONES (US) | 49,167.79 | 62.92 | -0.13% |
| FTSE 100 | 10,321.09 | 57.99 | -0.56% |
| HKSE | 25,925.65 | 52.42 | -0.20% |
| NASDAQ | 24,887.10 | 50.50 | 0.20% |
| Nikkei 225 | 60,312.52 | 224.84 | -0.37% |
| NZX 50 Index | 12,766.78 | 108.16 | -0.84% |
| S&P 500 | 7,173.91 | 8.83 | 0.12% |
| S&P/ASX 200 | 8,715.70 | 5.50 | -0.06% |
| SSE Composite Index | 4,086.34 | 6.44 | 0.16% |